The grey matter in the brain may hold vital clues for early, accurate detection in Alzheimer’s, and potentially also help pharma to find new drug treatments.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.